Literature DB >> 7145846

Prenatal diagnosis of hereditary tyrosinaemia: measurement of succinylacetone in amniotic fluid.

R Gagné, A Lescault, A Grenier, C Laberge, S B Mélançon, L Dallaire.   

Abstract

A method is proposed for prenatal diagnosis in pregnancies at risk of hereditary tryosinaemia. Affected fetuses were detected on the basis of the abnormal presence in the amniotic fluid of succinylacetone, a metabolite previously identified in sera and urines of patients suffering from hereditary tyrosinaemia. Our data show that the forty amniotic control samples had no detectable succinylacetone, while succinylacetone was found in three out of the thirteen cases at risk. Following the parents' decision, these three fetuses were aborted. The ten other mothers who brought their pregnancies to term had normal infants. Enzymatic analysis from two of their aborted fetuses' livers revealed an absence or a low activity of fumarylaceto-acetate hydrolase (EC 3.7.1.2) compared with control fetal livers of the same age.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7145846     DOI: 10.1002/pd.1970020307

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  13 in total

1.  Prenatal diagnosis of hereditary tyrosinaemia type I by determination of fumarylacetoacetase in chorionic villus material.

Authors:  E A Kvittingen; P P Guibaud; P Divry; G Mandon; M O Rolland; Y Domenichini; C Jakobs; E Christensen
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

2.  Prenatal diagnosis of tyrosinaemia type I by use of stable isotope dilution mass spectrometry.

Authors:  C Jakobs; E A Kvittingen; R Berger; A Haagen; W Kleijer; M Niermeijer
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

3.  Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.

Authors:  D Phaneuf; M Lambert; R Laframboise; G Mitchell; F Lettre; R M Tanguay
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

Review 4.  Current strategies for the treatment of hereditary tyrosinemia type I.

Authors:  Merja Ashorn; Sari Pitkänen; Matti K Salo; Markku Heikinheimo
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Tyrosinemia type I--diagnostic issues and prenatal diagnosis.

Authors:  Sunita Bijarnia; Ratna D Puri; Jean Ruel; George F Gray; Linda Jenkinson; Ishwar C Verma
Journal:  Indian J Pediatr       Date:  2006-02       Impact factor: 1.967

6.  Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease.

Authors:  Raymond D Hickey; Shennen A Mao; Jaime Glorioso; Joseph B Lillegard; James E Fisher; Bruce Amiot; Piero Rinaldo; Cary O Harding; Ronald Marler; Milton J Finegold; Markus Grompe; Scott L Nyberg
Journal:  Stem Cell Res       Date:  2014-05-14       Impact factor: 2.020

Review 7.  Prenatal diagnosis of inborn errors of metabolism with renal manifestations.

Authors:  E Harms
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

8.  Hereditary tyrosinemia type I: strong association with haplotype 6 in French Canadians permits simple carrier detection and prenatal diagnosis.

Authors:  S I Demers; D Phaneuf; R M Tanguay
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

9.  Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean.

Authors:  M De Braekeleer; J Larochelle
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

10.  Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).

Authors:  R M Tanguay; J P Valet; A Lescault; J L Duband; C Laberge; F Lettre; M Plante
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.